Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Data Collection Study From Donors and Recipients to Optimize Donor-recipient Matching in Liver Transplantation (OPTIMATCH-LT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03371264
Recruitment Status : Active, not recruiting
First Posted : December 13, 2017
Last Update Posted : August 6, 2019
Sponsor:
Collaborator:
Agence de La Biomédecine
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
A major limitation of liver transplantation is organ shortage. To avoid exposing patients to death on the waiting list, organs are used that would have been discarded few years ago. Graft allocation is regulated by the "agence de biomedecine" which establishes a national score. Each liver graft is proposed to the patient presenting the higher score. Acceptance or rejection of the graft only depends on the decision of each centre. We propose to submit a more efficient allocation model (enabling each proposed liver graft to be transplanted in the candidate whose transplantation will afford the greatest survival benefit after registration), by collecting and analysing variables from donors and candidates/recipients.

Condition or disease
Liver Transplantation

Layout table for study information
Study Type : Observational
Actual Enrollment : 9000 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Optimizing Donor-recipient Matching to Improve Survival After Registration on the Waiting List for Liver Transplantation: the OPTIMATCH LT Study
Actual Study Start Date : January 1, 2015
Actual Primary Completion Date : January 1, 2018
Estimated Study Completion Date : January 1, 2020

Resource links provided by the National Library of Medicine


Group/Cohort
Cohort R1 and Cohort T1
Cohort R1 (patients on the waiting list between 2009 and 2013) and Cohort T1 (transplanted patients between 2009 and 2013)
Cohort R2 and Cohort T2
Cohort R2 (patients on the waiting list in 2014) and Cohort T2 (transplanted patients in 2014)



Primary Outcome Measures :
  1. Survival analysis [ Time Frame: 5 years ]
    In view of the complexity of our project, different parallel approaches will be performed in order to establish predictive models

  2. Multi-state models [ Time Frame: 5 years ]
    In view of the complexity of our project, different parallel approaches will be performed in order to establish predictive models

  3. Decision tree analysis [ Time Frame: 5 years ]
    In view of the complexity of our project, different parallel approaches will be performed in order to establish predictive models


Secondary Outcome Measures :
  1. Number of each criterion of ECD (Donor population) [ Time Frame: 5 years ]
  2. Percentage of each criterion of ECD (Donor population) [ Time Frame: 5 years ]
  3. Donor scores (DRI, ELTR) (Donor population) [ Time Frame: 5 years ]
  4. mean score (Donor population) [ Time Frame: 5 years ]
  5. number of ECD criteria (Donor population) [ Time Frame: 5 years ]
  6. frequency of ECD criteria (Donor population) [ Time Frame: 5 years ]
  7. mean age of donors (Donor population) [ Time Frame: 5 years ]
  8. graft failure (Donor population) [ Time Frame: 5 years ]
  9. grafts with correct primary function (Donor population) [ Time Frame: 5 years ]
  10. epidemiological characteristics (Candidate population) [ Time Frame: 5 years ]
  11. indication for transplantation (Candidate population) [ Time Frame: 5 years ]
  12. severity of disease (Candidate population) [ Time Frame: 5 years ]
  13. comorbidities (Candidate population) [ Time Frame: 5 years ]
  14. time on waiting list (Candidate population) [ Time Frame: 5 years ]
  15. Proportion of early deaths after transplantation (Candidate population) [ Time Frame: 5 years ]
  16. drop-outs for worsening (Candidate population) [ Time Frame: 5 years ]
    Description of events occurring on waiting list

  17. deaths on the waiting list (Candidate population) [ Time Frame: 5 years ]
  18. median time of occurrence (Candidate population) [ Time Frame: 5 years ]
    Description of events occurring on waiting list

  19. number of drop-outs for improvement (Candidate population) [ Time Frame: 5 years ]
  20. percentages of drop-outs for improvement (Candidate population) [ Time Frame: 5 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Population of proposed donors and the population of patients registered on the national waiting list from 2009 to 2014 (Agence de Biomédecine)
Criteria

Inclusion Criteria:

  • Liver transplant candidates : All adult LT candidates listed on the French wait list between 2009 and 2014 and followed prospectively by the mean yearly follow-up under the control of ABM.
  • Donors : all adults donors registered over the same 2009-2014 period, including donors whose livers were procured and transplanted, whose liver were procured and discarded, and donors in whom liver was not harvested.

Exclusion Criteria:

  • Pediatric recipients
  • Pediatric donors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03371264


Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Agence de La Biomédecine
Investigators
Layout table for investigator information
Principal Investigator: Cyrille Feray, MD/PhD Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT03371264    
Other Study ID Numbers: P13639
First Posted: December 13, 2017    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Liver transplantation
Allocation process
Extended-criteria donors
Survival